Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.66 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.66 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26288696 | 0.98 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5497908 | 0.98 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13589901 | 0.98 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Bromide SCHEMBL27157764 | 0.86 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Bromide SCHEMBL15775463 | 0.86 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Bromide SCHEMBL15775912 | 0.86 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL24028165 | 0.84 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL15790545 | 0.84 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10511270 | 0.84 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16570342 | 0.84 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306085-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | APODACA RICHARD | 2008-12-11 | — | — | US | disclosed |
| US-7429586-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICLAS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7186732-B2 | Non-imidazole aryloxyalkylamines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | APODACA RICHARD | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235049-A1 | 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders | HRH4, HRH3, HRH2 | CHRNB2 61/4885CHRNA4 30/4885CHRNB4 50/4885 |
| US-20080306085-A1 | NON-IMIDAZOLE ARYLOXYALKYLAMINES | HNMT, HRH2, HRH3 | CHRNB2 215/4885CHRNA4 435/4885CHRNB4 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.